Positive topline data from a phase 2 trial show HT-6184, an allosteric NEK7/NLRP3 inflammasome inhibitor, improves ...

At the 2024 American Society of Hematology Annual Meeting & Exposition (ASH), a variety of promising therapies for the ...

Lutetium 177 dotatate showed activity and met the PFS end point in patients with surgery- or radiation-refractory grade 2/3 ...

The FDA granted breakthrough therapy designation to dostarlimab for locally advanced dMMR/MSI-H rectal cancer, highlighting ...

Memorial Sloan Kettering Cancer Center physicians describe challenges in diagnosis, patient care, and the potential expansion of telehealth in this continuation of November's coverfeature.

Paolo Ghia, MD, PhD, provides an overview of the CAPTIVATE trial, uncovering what investigators sought to evaluate.

The NCCN has endorsed the Prolaris prostate cancer prognostic test, reinforcing its position as a critical tool in prostate ...

FDA approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma that is not ...

The following list will provide you with suggestions for identifying the go-getters and how to include them in your practice or on your team.

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment ...

Recent cancer treatment breakthroughs include FDA approvals for zenocutuzumab and durvalumab, and sacituzumab tirumotecan gained breakthrough therapy status. In addition, sonodynamic therapy shows ...

Cladribine plus venetoclax improved complete response and CR with incomplete count recovery rates in MRD-negative patients ...